trending Market Intelligence /marketintelligence/en/news-insights/trending/n-m4mmk5n0chgeuathwlig2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Ono Pharmaceutical secures license for antibody discovery platform

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles


Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018

Ono Pharmaceutical secures license for antibody discovery platform

Ono Pharmaceutical Co. Ltd. secured a global license for Ligand Pharmaceuticals' OmniAb platform to discover antibody-based treatments for diseases.

The agreement provides for the OmniRat, OmniMouse and OmniFlic platforms to formulate fully human mono- and bispecific antibodies.

Ligand will receive an undisclosed annual payment for access to the platform as well as milestone-related payments and royalty on sales of products derived from the platform.